Business Context and Reporting Period
This Form 6-K filing by pSivida Limited (a foreign issuer) covers the month of January 2007, with the report dated January 9, 2007. The registrant is based in Perth, Western Australia, and files annual reports on Form 20-F. The filing incorporates by reference a press release (Exhibit 99.1) regarding a new corporate agreement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a material event rather than a financial statement.
Material Changes and Corporate Events
- Licensing Agreement: pSivida Limited signed a drug delivery licensing agreement with Faber Research LLC.
- Registration Statements: The information is incorporated into three active Registration Statements on Form F-3 (Nos. 333-132776, 333-132777, and 333-135428).
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, specific risk factors, or details on contingencies beyond the announcement of the licensing agreement. No unusual items or outlook projections are explicitly stated in the provided text.
Investor Verification Checklist
- Verify the specific terms, scope, and financial implications of the drug delivery licensing agreement with Faber Research LLC by reviewing the full text of Exhibit 99.1.
- Confirm the status of the three referenced Form F-3 registration statements to understand potential capital raising activities.
- Review subsequent filings for any financial impact resulting from this agreement, as no immediate financial data is provided in this 6-K.